Budget 2026 | Biopharma SHAKTI: The scheme sits at the intersection of public health imperatives and industrial policy.

Discover India's Biopharma Shakti initiative: a ₹10,000-crore plan to enhance biologics, biosimilars, and healthcare standards.

Union Budget 2026 unveiled a Rs 10,000 crore Biopharma Shakti mission to boost advanced medicine production, tackle rising diabetes and obesity, and strengthen India’s fight against non-communicable ...

While policy shifts and leadership shakeups at institutions like the Food and Drug Administration dominated headlines in 2025, drugmakers would do well to sift through the noise and remain focused on ...

Finance Minister Nirmala Sitharaman announces Biopharma Shakti, a ₹10,000 crore plan to boost biologics, biosimilars, ...

The Finance Minister has envisioned Biopharma SHAKTI (Strategy for Healthcare Advancement through Knowledge, Technology and Innovation) with an outlay of ₹ 10,000 crores over the next 5 years.

Industry leaders have said the Union Budget 2026 has laid the groundwork for a major shift in India's pharmaceutical sector, with the Biopharma SHAKTI initiative expected to reduce reliance on ...

A view of Takeda Pharmaceutical Company in Cambridge. Takeda is the largest biopharma employer in the state. (Spencer Grant/GHI/UCG/Universal Images Group via Getty Images) The state's biopharma ...

What To Know: Sunshine Biopharma, through its wholly owned Canadian subsidiary Nora Pharma, announced the launch of Pravastatin, a lipid metabolism regulator. The stock was up more than 17% at the ...

Shares of Quantum BioPharma Ltd (NASDAQ:QNTM) are on watch Monday morning following a series of updates regarding its lead drug candidate for multiple sclerosis, Lucid-MS. Here’s what investors need ...

Symbolic milestone for new buffer media station: Rentschler Biopharma underscores its commitment to the Laupheim headquarters and to the future of Germany and Europe as leading biotechnology hubs ...

Quantum BioPharma (NASDAQ: QNTM) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and ...